Cargando…
Clinicopathologic features and outcomes following surgery for pancreatic adenosquamous carcinoma
BACKGROUND: Pancreatic adenosquamous carcinoma (ASC) is a rare pancreatic malignancy subtype. We investigated the clinicopathological features and outcome of pancreatic ASC patients after surgery. METHODS: The medical records of 12 patients with pancreatic ASC undergoing surgical treatment (1993 to...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2543014/ https://www.ncbi.nlm.nih.gov/pubmed/18764955 http://dx.doi.org/10.1186/1477-7819-6-95 |
_version_ | 1782159167121784832 |
---|---|
author | Hsu, Jun-Te Chen, Han-Ming Wu, Ren-Chin Yeh, Chun-Nan Yeh, Ta-Sen Hwang, Tsann-Long Jan, Yi-Yin Chen, Miin-Fu |
author_facet | Hsu, Jun-Te Chen, Han-Ming Wu, Ren-Chin Yeh, Chun-Nan Yeh, Ta-Sen Hwang, Tsann-Long Jan, Yi-Yin Chen, Miin-Fu |
author_sort | Hsu, Jun-Te |
collection | PubMed |
description | BACKGROUND: Pancreatic adenosquamous carcinoma (ASC) is a rare pancreatic malignancy subtype. We investigated the clinicopathological features and outcome of pancreatic ASC patients after surgery. METHODS: The medical records of 12 patients with pancreatic ASC undergoing surgical treatment (1993 to 2006) were retrospectively reviewed. Survival data of patients with stage IIB pancreatic adenocarcinoma and ASC undergoing surgical resection were compared. RESULTS: Symptoms included abdominal pain (91.7%), body weight loss (83.3%), anorexia (41.7%) and jaundice (25.0%). Tumors were located at pancreatic head in 5 (41.7%) patients, tail in 5 (41.7%), and body in 4 (33.3%). Median tumor size was 6.3 cm. Surgical resection was performed on 7 patients, bypass surgery on 3, and exploratory laparotomy with biopsy on 2. No surgical mortality was identified. Seven (58.3%) and 11 (91.7%) patients died within 6 and 12 months of operation, respectively. Median survival of 12 patients was 4.41 months. Seven patients receiving surgical resection had median survival of 6.51 months. Patients with stage IIB pancreatic ASC had shorter median survival compared to those with adenocarcinoma. CONCLUSION: Aggressive surgical management does not appear effective in treating pancreatic ASC patients. Strategies involving non-surgical treatment such as chemotherapy, radiotherapy or target agents should be tested. |
format | Text |
id | pubmed-2543014 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-25430142008-09-19 Clinicopathologic features and outcomes following surgery for pancreatic adenosquamous carcinoma Hsu, Jun-Te Chen, Han-Ming Wu, Ren-Chin Yeh, Chun-Nan Yeh, Ta-Sen Hwang, Tsann-Long Jan, Yi-Yin Chen, Miin-Fu World J Surg Oncol Research BACKGROUND: Pancreatic adenosquamous carcinoma (ASC) is a rare pancreatic malignancy subtype. We investigated the clinicopathological features and outcome of pancreatic ASC patients after surgery. METHODS: The medical records of 12 patients with pancreatic ASC undergoing surgical treatment (1993 to 2006) were retrospectively reviewed. Survival data of patients with stage IIB pancreatic adenocarcinoma and ASC undergoing surgical resection were compared. RESULTS: Symptoms included abdominal pain (91.7%), body weight loss (83.3%), anorexia (41.7%) and jaundice (25.0%). Tumors were located at pancreatic head in 5 (41.7%) patients, tail in 5 (41.7%), and body in 4 (33.3%). Median tumor size was 6.3 cm. Surgical resection was performed on 7 patients, bypass surgery on 3, and exploratory laparotomy with biopsy on 2. No surgical mortality was identified. Seven (58.3%) and 11 (91.7%) patients died within 6 and 12 months of operation, respectively. Median survival of 12 patients was 4.41 months. Seven patients receiving surgical resection had median survival of 6.51 months. Patients with stage IIB pancreatic ASC had shorter median survival compared to those with adenocarcinoma. CONCLUSION: Aggressive surgical management does not appear effective in treating pancreatic ASC patients. Strategies involving non-surgical treatment such as chemotherapy, radiotherapy or target agents should be tested. BioMed Central 2008-09-03 /pmc/articles/PMC2543014/ /pubmed/18764955 http://dx.doi.org/10.1186/1477-7819-6-95 Text en Copyright © 2008 Hsu et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Hsu, Jun-Te Chen, Han-Ming Wu, Ren-Chin Yeh, Chun-Nan Yeh, Ta-Sen Hwang, Tsann-Long Jan, Yi-Yin Chen, Miin-Fu Clinicopathologic features and outcomes following surgery for pancreatic adenosquamous carcinoma |
title | Clinicopathologic features and outcomes following surgery for pancreatic adenosquamous carcinoma |
title_full | Clinicopathologic features and outcomes following surgery for pancreatic adenosquamous carcinoma |
title_fullStr | Clinicopathologic features and outcomes following surgery for pancreatic adenosquamous carcinoma |
title_full_unstemmed | Clinicopathologic features and outcomes following surgery for pancreatic adenosquamous carcinoma |
title_short | Clinicopathologic features and outcomes following surgery for pancreatic adenosquamous carcinoma |
title_sort | clinicopathologic features and outcomes following surgery for pancreatic adenosquamous carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2543014/ https://www.ncbi.nlm.nih.gov/pubmed/18764955 http://dx.doi.org/10.1186/1477-7819-6-95 |
work_keys_str_mv | AT hsujunte clinicopathologicfeaturesandoutcomesfollowingsurgeryforpancreaticadenosquamouscarcinoma AT chenhanming clinicopathologicfeaturesandoutcomesfollowingsurgeryforpancreaticadenosquamouscarcinoma AT wurenchin clinicopathologicfeaturesandoutcomesfollowingsurgeryforpancreaticadenosquamouscarcinoma AT yehchunnan clinicopathologicfeaturesandoutcomesfollowingsurgeryforpancreaticadenosquamouscarcinoma AT yehtasen clinicopathologicfeaturesandoutcomesfollowingsurgeryforpancreaticadenosquamouscarcinoma AT hwangtsannlong clinicopathologicfeaturesandoutcomesfollowingsurgeryforpancreaticadenosquamouscarcinoma AT janyiyin clinicopathologicfeaturesandoutcomesfollowingsurgeryforpancreaticadenosquamouscarcinoma AT chenmiinfu clinicopathologicfeaturesandoutcomesfollowingsurgeryforpancreaticadenosquamouscarcinoma |